@Jlivermore - The RMS stock, has gone from $1.55 in May to a high of over $4.00 in early September. A very substantial run up. The increase in share price correlates with coverage being initiated by Craig-Hallum in the middle of June. Coincidence? I do not think so. (Craig-Hallum reiterated a buy rating with $5.50 price target after meeting with the management in September!)
Today's price action, which surprised me, dropped the price to an intraday low of $3.25.I see this as shaking out the weak hands and healthy for continued long term stock price appreciation.
The RMS strategy of developing partnerships with big pharma is starting to bare fruit. The sales of Grifols/Xemblify's subQ formulation commences in Q4. Approval outside of the U.S should follow. This revenue stream will ramp up beginning 2020.
The migration to home infusion for cost and convenience reasons will encourage drug makers to reconfigure drug formulation so they can be administered at home via SubQ.
RMS received another favorable ruling against EDEM in NY.(This is the second favorable ruling. The first was in TX.) The NY suit was the most expensive of the suits and this will save a lot of legal expenses. With two strikes against EDEM the incentive for settlement grows.
The RMS story remains largely untold. Uplisting to a major exchange expected and will bring additional buyers and coverage. Possibly becoming part of a Russell indexed fund down the line.
News 
Market Data 
Discover 
